CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer-Reference-Cited by-同舟云学术

CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer

Published:2015-06-24 Issue:2 Volume:152 Page:337-346
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Black Justin L.,Harrell J. Chuck,Leisner Tina M.,Fellmeth Melissa J.,George Samuel D.,Reinhold Dominik,Baker Nicole M.,Jones Corbin D.,Der Channing J.,Perou Charles M.,Parise Leslie V.

Funder

National Heart, Lung, and Blood Institute

North Carolina Translational and Clinical Sciences Institute

American Heart Association

National Cancer Institute

North Carolina Biotechnology Center

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-015-3458-4.pdf

Reference41 articles.

1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29. doi: 10.3322/caac.21208

2. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkila P, Heikkinen T, Nevanlinna H, Akslen LA, Begin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF, Garcia-Closas M, Caldas C, Pharoah PD, Huntsman D (2010) Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 7(5):e1000279. doi: 10.1371/journal.pmed.1000279

3. Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, Spellman PT, Shokat KM, Wyrobek AJ, Bissell MJ, McCormick F, Kuo WL, Mills GB, Gray JW, Korn WM (2009) Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 69(2):565–572. doi: 10.1158/0008-5472.CAN-08-3389

4. Hoeflich KP, O’Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman LS, Lackner MR (2009) In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res: Off J Am Assoc Cancer Res 15(14):4649–4664. doi: 10.1158/1078-0432.CCR-09-0317

5. Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B, Wick MJ, Alvarez C, Cavazos A, Mangold GL, Patnaik A (2012) The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 18(8):2316–2325. doi: 10.1158/1078-0432.CCR-11-2381

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In silico fragment-based discovery of CIB1-directed anti-tumor agents by FRASE-bot;Nature Communications;2024-07-02

2. Small-Molecule Disruptors of the Interaction between Calcium- and Integrin-Binding Protein 1 and Integrin α_IIbβ₃ as Novel Antiplatelet Agents;ACS Pharmacology & Translational Science;2024-05-29

3. Deubiquitination of CIB1 by USP14 promotes lenvatinib resistance via the PAK1-ERK1/2 axis in hepatocellular carcinoma;International Journal of Biological Sciences;2024

4. Identification of calcium and integrin-binding protein 1 as a reprogrammed glucose metabolism mediator to restrict immune cell infiltration in the stromal compartment of pancreatic ductal adenocarcinoma;Frontiers in Immunology;2023-04-28

5. Strategies for Targeting CIB1: A Challenging Drug Target;Current Pharmaceutical Design;2022-08